Pay in 4 interest-free payments of $6.53 Learn more
Ships within 48 hours · Estimated delivery Oct 10 - Oct 15
Employers would save on sick days, burnout, and the downstream costs of managing chronic diseases that are directly tied to obesity
In fact, GLP-1 agonists are the fastest growing class of diabetes medicines with a 36% five-year compound annual growth rate and accounting for 16% of prescriptions in 2023
Smith, S.D
Important considerations include: Off-label use for cosmetic indications Risks associated with improper dosing, frequency, or sourcing Temporary and non-permanent effects Need for discontinuation if adverse effects occur At SkinDot Clinics, injections are administered only by trained medical staff following assessment by a qualified dermatologist
Sarkaki A, et al
